Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial

Gastroenterology

Volumn 132, Issue 5, 2007, Pages 1672-1683

  Targan, Stephan R ^a   Feagan, Brian G ^b   Fedorak, Richard N ^c   Lashner, Bret A ^d   Panaccione, Remo ^e   Present, Daniel H ^f   Spehlmann, Martina E ^g   Rutgeerts, Paul J ^h   Tulassay, Zsolt ⁱ   Volfova, Miroslava ^j   Wolf, Douglas C ^k   Hernandez, Chito ^l   Bornstein, Jeffrey ^l   Sandborn, William J ^m  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g AK St Georg   (Germany)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j Hepato Gastroenterology HK   (Czech Republic)

^k Atlanta Gastroenterology Associates   (United States)

^l ELAN PHARMACEUTICALS   (United States)

^m MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIANAL ABSCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SINUSITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 34247884424     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.03.024     Document Type: Article

References (22)

1. Lobb R.R., and Hemler M.E. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 94 (1994) 1722-1728
2. Giancotti F.G. A structural view of integrin activation and signaling. Dev Cell 4 (2003) 149-151
3. von Andrian U.H., and Engelhardt B. a4 Integrins as therapeutic targets in autoimmune disease. N Engl J Med 348 (2003) 68-72
4. Gordon F.H., Lai C.W., Hamilton M.I., Allison M.C., Srivastava E.D., Fouweather M.G., Donoghue S., Greenlees C., Subhani J., Amlot P.L., and Pounder R.E. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121 (2001) 268-274
5. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnalek P., Zadorova Z., Palmer T., Donoghue S., and Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003) 24-32
6. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., Panaccione R., Sanders M., Schreiber S., Targan S., van Deventer S., Goldblum R., Despain D., Hogge G.S., Rutgeerts P., International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group, and Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
7. Best W.R., Becktel J.M., Singleton J.W., and Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
8. Irvine E.J., Feagan B., Rochon J., Archambault A., Fedorak R.N., Groll A., Kinnear D., Saibil F., McDonald J.W., and Canadian Crohn's Relapse Prevention Trial Study Group. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 106 (1994) 287-296
9. Brazier J.E., Harper R., Jones N.M., O'Cathain A., Thomas K.J., Usherwood T., and Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305 (1992) 160-164
10. Su C., Lichtenstein G.R., Krok K., Brensinger C.M., and Lewis J.D. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 126 (2004) 1257-1269
11. Kapsoritakis A.N., Koukourakis M.I., Sfiridaki A., Potamianos S.P., Kosmadaki M.G., Koutroubakis I.E., and Kouroumalis E.A. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 96 (2001) 776-781
12. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., Verbeeck J., Geboes K., Robberecht W., and Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
13. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
14. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., and Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
15. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., Barkhof F., Radue E.W., Jager H.R., and Clifford D.B. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
16. Lewis J.D. C-reactive protein: anti-placebo or predictor of response. Gastroenterology 129 (2005) 1114-1116
17. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W., and International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 (2003) 15-23
18. Tubridy N., Behan P.O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C.P., Hughes R.A., Palace J., Sharrack B., Swingler R., Young C., Moseley I.F., MacManus D.G., Donoghue S., Miller D.H., and The UK Antegren Study Group. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 53 (1999) 466-472
19. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W., and AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
20. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., Lublin F.D., Weinstock-Guttman B., Wynn D.R., Lynn F., Panzara M.A., Sandrock A.W., and SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 (2006) 911-923
21. Tysabri [package insert]. San Diego, CA: Elan, and Cambridge, MA: Biogen Idec.
22. Sands B., Siegel C., Hass S., Miller D., White J., Johnson R., et al. Crohn's disease patients' willingness to accept the risks of serious adverse events in exchange for clinical benefits (abstr). Gastroenterology 130 Suppl 2 (2006) A656